TITLE:
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

CONDITION:
Pancreatic Cancer

INTERVENTION:
Tarceva (erlotinib HCl, OSI-774)

SUMMARY:

      The purpose of this study is to determine if OSI-774 will improve overall survival when
      combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with
      pancreatic cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

        Histologically or cytologically confirmed diagnosis of adenocarcinoma of the
        pancreas;cancer which is unresectable, locally advanced or metastatic.

        Must have evidence of disease (clinical or radiological). Male or female, 18 years or
        older. Patients may have received prior radiation treatment for management of local
        disease providing that disease progression has been documented.

        All toxicities have resolved, and the last fraction of radiation treatment was completed
        at least 4 weeks prior to randomization.

        Patients may not have received prior chemotherapy, other then 5FU (+/- folic acid) or
        gemcitabine given concurrently with radiation treatment as a 'radiosensitiser.'
      
